UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) | --- | --- | |---------------------- ...

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive license agreement with ALK-Abelló to commercialize neffy® in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royaltiesWell-capitalized with $349.6 million in cash, cash equivalents and short ...

On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. SPRY.The agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, except in the U.S., Australia, New Zealand, Japan, and China.In August, the FDA approved ARS Pharmaceuticals’ Neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), for adult and pediatric patients.Neffy is a ...

Shares of ARS Pharmaceuticals, Inc. (SPRY) have gained 10.4% over the past four weeks to close the last trading session at $15.32, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25.67 indicates a potential upside of 67.6%.The mean estimate comprises three short-term price targets with a standard deviation of $4.04. While the lowest estimate of $22 indicates a 43.6% increase fr ...

Core Viewpoint - The article emphasizes the importance of identifying and sustaining stock price trends for successful short-term investing, highlighting the need for strong fundamentals and positive earnings revisions to maintain momentum [1][2]. Group 1: Stock Performance - ARS Pharmaceuticals, Inc. (SPRY) has shown a solid price increase of 55.1% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also increased by 4.9% over the last four weeks, suggesting that the upward trend is still intact [5]. - Currently, SPRY is trading at 86.1% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - SPRY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like SPRY that are on an upward trend supported by strong fundamentals [3][8]. - It also mentions the availability of over 45 Zacks Premium Screens tailored to different investing styles, which can help in finding winning stock picks [8].

Core Insights - ARS Pharmaceuticals is presenting seven abstracts at the 2024 ACAAI Annual Scientific Meeting, focusing on intranasal epinephrine administration and its implications for treating severe allergic reactions [1][2] Group 1: Company Overview - ARS Pharmaceuticals is a biopharmaceutical company dedicated to protecting at-risk patients from severe allergic reactions that could lead to anaphylaxis [11] - The company has developed neffy®, the first and only needle-free treatment for Type I allergic reactions, including anaphylaxis, for patients weighing 30 kg or more [2][7] Group 2: Research and Development - The research presented at the ACAAI meeting includes studies on cardiovascular safety, real-world administration data in pediatric patients, and the efficacy of intranasal epinephrine [1][2] - Key studies include the cardiovascular safety of intramuscular versus intranasal epinephrine, blood pressure and pulse rate changes during allergic reactions, and pharmacokinetic profiles among different epinephrine products [3][4][5] Group 3: Market Context - Approximately 40 million people in the U.S. experience Type I allergic reactions, but only 3.3 million have an active epinephrine auto-injector prescription, with only half consistently carrying it [5] - The limitations of current epinephrine auto-injectors, such as fear of needles and lack of portability, highlight the potential market for neffy® [4][5]

ARS Pharmaceuticals, Inc. (SPRY) closed the last trading session at $14.52, gaining 9.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.67 indicates a 76.8% upside potential. The average comprises three short-term price targets ranging from a low of $22 to a high of $30, with a standard deviation of $4.04. While the lowest estimate indicates an increase of 51.5% from the curre ...

ARS Pharmaceuticals, Inc. (SPRY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Ind ...

vgajic/E+ via Getty Images Investment Overview The San Diego based biotech ARS Pharmaceutical's (NASDAQ:SPRY) share price is up nearly 120% year-to-date, and at the end of August, shares made a quick >20% gain, after its lead and only product, neffy, a nasal spray, was approved for commercial use by the FDA, ahead of schedule, for the treatment of Type I Allergic Reactions. In its latest, Q2 2024 quarterly report / 10Q submission, ARS provides basic information around neffy as follows: ARS-1 (brand name nef ...

EURneffy offers adults and children (≥30 kg) in Europe living with severe allergic reactions the first new delivery method for adrenaline in more than 30 years in the EU European Commission decision follows FDA approval in the United States on August 9, 2024 SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to the development of products to better protect patients from severe allergic reactions that could lead to anaphylaxis, announc ...